Medpace Holdings Inc. (MEDP)
Medpace: Profit Margin, Growth, And Repurchase Program Will Trump Legislative Headwinds (Rating Upgrade)
For this year, Medpace expects that its revenues will increase by 17.1%, which is an excellent growth rate. From 2019 to Q2 2025, Medpace's outstanding common shares declined by 22.16%, creating value for its investors. In the first half of 2025, the company had a capex-to-revenues ratio of 1.39%, which contributed to the company's high net profit margin.
Medpace (MEDP) Is Up 5.41% in One Week: What You Should Know
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Medpace: Return Of The Mack, With Double-Digit Revenue Growth
Medpace delivered a stunning Q2 2025, with double-digit revenue and net new awards growth, defying widespread healthcare sector pessimism. The company achieved 14% YoY revenue growth and 18.6% EBITDA growth, far surpassing expectations, and increased guidance for the year. Management accelerated opportunistic share buybacks, returning $908 million to shareholders in the first half of 2025, demonstrating exceptional capital allocation.
Should You Buy Medpace (MEDP) After Golden Cross?
After reaching an important support level, Medpace Holdings, Inc. (MEDP) could be a good stock pick from a technical perspective. MEDP recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
What Makes Medpace (MEDP) a New Strong Buy Stock
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Medpace Holdings, Inc. (MEDP) Q2 2025 Earnings Call Transcript
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants August James Troendle - Chairman & CEO Jesse J. Geiger - President Kevin M.
Medpace's Global CRO Reach Lends Credibility For Its 2025 Revenue Guidance Increase
Medpace's Global CRO Reach Lends Credibility For Its 2025 Revenue Guidance Increase
This Clinical Trials Stock Just Soared 40%. What Caused It to Pop.
If gains hold, that'd be the stock's largest single-day increase on record.
Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates
Medpace (MEDP) came out with quarterly earnings of $3.1 per share, beating the Zacks Consensus Estimate of $3 per share. This compares to earnings of $2.75 per share a year ago.
Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know
Medpace (MEDP) reached $319.16 at the closing of the latest trading day, reflecting a +1.38% change compared to its last close.
Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Medpace (MEDP) stood at $328.24, denoting a +2.27% move from the preceding trading day.
